Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives
Over the past few decades, treatment of multidrug-resistant (MDR)/extensively drug-resistant (XDR) tuberculosis (TB) has been challenging because of its prolonged duration (up to 20–24 months), toxicity, costs and sub-optimal outcomes. After over 40 years of neglect, two new drugs (bedaquiline and d...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
European Respiratory Society
2019-05-01
|
Series: | European Respiratory Review |
Online Access: | http://err.ersjournals.com/content/28/152/190035.full |